Compare · ADXS vs FLXN
ADXS vs FLXN
Side-by-side comparison of Advaxis, Inc. (ADXS) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXS and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN is the larger of the two at $458.9M, about 8.2x ADXS ($56.0M).
- FLXN has more recent analyst coverage (7 ratings vs 0 for ADXS).
- Company
- Advaxis, Inc.
- Flexion Therapeutics, Inc.
- Price
- $0.25-15.74%
- $25.11-0.20%
- Market cap
- $56.0M
- $458.9M
- 1M return
- -
- -1.91%
- 1Y return
- -
- -1.57%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 7
Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest ADXS
- OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
- SEC Form 15-12G filed by Advaxis, Inc.
- SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)
- Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 10-K filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)